Immune Checkpoint Inhibitor-Induced Diabetes Presenting As Diabetic Ketoacidosis: A Case Report. (PubMed, Cureus) - Sep 8, 2026 - "A 51-year-old woman with BRAF V600E-positive metastatic melanoma developed diabetic ketoacidosis (DKA) three weeks after commencing combination immunotherapy with nivolumab and ipilimumab, despite a normal baseline endocrine and metabolic assessment. She was treated according to standard DKA protocols, transitioned to long-term insulin therapy, and her immunotherapy was de-escalated to single-agent nivolumab because of concern for recurrent endocrine toxicity. This case illustrates the rapid and unpredictable onset of ICI-induced insulin-deficient diabetes, which occurred despite normal baseline investigations in this patient, and highlights the need for vigilant glucose monitoring in patients receiving combination checkpoint inhibitor therapy."
Checkpoint inhibition • Journal • Diabetes • Melanoma • Metabolic Disorders • Oncology • Solid Tumor • Type 1 Diabetes Mellitus • BRAF
|
|
Kaijanee Kugavarathan; Kiran Lama; Ravi Yadav; Victoria P John; Yousri Waziri
|